Skip to content

IDENIX PHARMACEUTICALS INC

Delisted

CIK 1093649fmd_060X0KY45TNAG8Y0H89DAE86YDManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Jun 30, 2014, 18 periods

Latest annual · FY2013

Millions
Total revenues
0
Gross profit
(0)
Operating income
(124)
Net income
(122)
Free cash flow
(110)

Latest quarter · Q2 FY2014

Millions
Total revenues
(26)
Operating income
(65)
Net income
(64)
Free cash flow
(33)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2010 to FY2013
-64.2%

IDENIX PHARMACEUTICALS INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2013FY2012ChangeSource
Revenue$469,00010-K 2014-02-27 · proof
Gross profit-$246,00010-K 2014-02-27 · proof
Operating income-$123.7 million-$35.4 million10-K 2014-02-27 · proof
Net income-$122.3 million-$32.4 million10-K 2014-02-27 · proof
Cash from operating activities-$109.1 million-$81.6 million10-K 2014-02-27 · proof
Free cash flow-$110.2 million-$82.7 million10-K 2014-02-27 · proof
Total assets$141 million$250.9 million-43.8%10-K 2014-02-27 · proof
Total liabilities$35 million$31.7 million+10.4%10-K 2014-02-27 · proof
Cash and cash equivalents$122 million$230.8 million-47.1%10-K 2014-02-27 · proof
What was IDENIX PHARMACEUTICALS INC's revenue in fiscal 2013?
IDENIX PHARMACEUTICALS INC reported revenue of $469,000 for fiscal 2013 (the year ended Dec 31, 2013). Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What was IDENIX PHARMACEUTICALS INC's gross profit in fiscal 2013?
IDENIX PHARMACEUTICALS INC reported gross profit of -$246,000 for fiscal 2013 (the year ended Dec 31, 2013). Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What was IDENIX PHARMACEUTICALS INC's operating income in fiscal 2013?
IDENIX PHARMACEUTICALS INC reported operating income of -$123.7 million for fiscal 2013 (the year ended Dec 31, 2013), against -$35.4 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What was IDENIX PHARMACEUTICALS INC's net income in fiscal 2013?
IDENIX PHARMACEUTICALS INC reported net income of -$122.3 million for fiscal 2013 (the year ended Dec 31, 2013), against -$32.4 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What was IDENIX PHARMACEUTICALS INC's cash from operating activities in fiscal 2013?
IDENIX PHARMACEUTICALS INC reported cash from operating activities of -$109.1 million for fiscal 2013 (the year ended Dec 31, 2013), against -$81.6 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What was IDENIX PHARMACEUTICALS INC's free cash flow in fiscal 2013?
IDENIX PHARMACEUTICALS INC reported free cash flow of -$110.2 million for fiscal 2013 (the year ended Dec 31, 2013), against -$82.7 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What are IDENIX PHARMACEUTICALS INC's total assets?
As of Dec 31, 2013, IDENIX PHARMACEUTICALS INC reported total assets of $141 million, against $250.9 million a year earlier (-43.8%). Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What are IDENIX PHARMACEUTICALS INC's total liabilities?
As of Dec 31, 2013, IDENIX PHARMACEUTICALS INC reported total liabilities of $35 million, against $31.7 million a year earlier (+10.4%). Source: the 10-K filed with the SEC on Feb 27, 2014. SEC
What are IDENIX PHARMACEUTICALS INC's cash and cash equivalents?
As of Dec 31, 2013, IDENIX PHARMACEUTICALS INC reported cash and cash equivalents of $122 million, against $230.8 million a year earlier (-47.1%). Source: the 10-K filed with the SEC on Feb 27, 2014. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1093649&period_type=annual&limit=5"

Information only, not investment advice.